Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Christina Schaub - , Universität Bonn (Autor:in)
  • Sied Kebir - , Universität Bonn, Universität Duisburg-Essen (Autor:in)
  • Nina Junold - , Universität Bonn (Autor:in)
  • Elke Hattingen - , Universität Bonn (Autor:in)
  • Niklas Schäfer - , Universität Bonn, Universität Duisburg-Essen (Autor:in)
  • Joachim P. Steinbach - , Universitätsklinikum Frankfurt (Autor:in)
  • Astrid Weyerbrock - , Albert-Ludwigs-Universität Freiburg (Autor:in)
  • Peter Hau - , Universität Regensburg (Autor:in)
  • Roland Goldbrunner - , Universität zu Köln (Autor:in)
  • Michael Niessen - , Universität Bonn (Autor:in)
  • Frederic Mack - , Universität Bonn (Autor:in)
  • Moritz Stuplich - , Universität Bonn (Autor:in)
  • Theophilos Tzaridis - , Universität Bonn (Autor:in)
  • Oliver Bähr - , Universitätsklinikum Frankfurt (Autor:in)
  • Rolf Dieter Kortmann - , Universität Leipzig (Autor:in)
  • Uwe Schlegel - , Ruhr-Universität Bochum (Autor:in)
  • Friederike Schmidt-Graf - , Technische Universität München (Autor:in)
  • Veit Rohde - , Georg-August-Universität Göttingen (Autor:in)
  • Christian Braun - , Eberhard Karls Universität Tübingen (Autor:in)
  • Mathias Hänel - , Klinikum Chemnitz gGmbH (Autor:in)
  • Michael Sabel - , Heinrich Heine Universität Düsseldorf (Autor:in)
  • Rüdiger Gerlach - , Fresenius AG (Autor:in)
  • Dietmar Krex - , Klinik und Poliklinik für Neurochirurgie, Technische Universität Dresden (Autor:in)
  • Claus Belka - , Ludwig-Maximilians-Universität München (LMU) (Autor:in)
  • Hartmut Vatter - , Universität Bonn (Autor:in)
  • Martin Proescholdt - , Universität Regensburg (Autor:in)
  • Ulrich Herrlinger - , Universität Bonn (Autor:in)
  • Martin Glas - , Universität Bonn, Universität Duisburg-Essen (Autor:in)

Abstract

Background: We evaluated patterns of tumor growth in patients with newly diagnosed MGMT-non-methylated glioblastoma who were assigned to undergo radiotherapy in conjunction with bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ) within the randomized phase II GLARIUS trial. Methods: In 142 patients (94 BEV/IRI, 48 TMZ), we reviewed magnetic resonance imaging scans at baseline and first tumor recurrence. Based on contrast-enhanced T1-weighted and fluid-attenuated inversion recovery images, we assessed tumor growth patterns and tumor invasiveness. Tumor growth patterns were classified as either multifocal or local at baseline and recurrence; at first recurrence, we additionally assessed whether distant lesions appeared. Invasiveness was determined as either diffuse or non-diffuse. Associations with treatment arms were calculated using Fisher’s exact test. Results: At baseline, 115 of 142 evaluable patients (81%) had a locally confined tumor. Between treatment arms, there was no significant difference in the fraction of tumors that changed from an initially local tumor growth pattern to a multifocal pattern (12 and 13%, p = 0.55). Distant lesions appeared in 17% (BEV/IRI) and 13% (TMZ) of patients (p = 0.69). 15% of patients in the BEV/IRI arm and 8% in the TMZ arm developed a diffuse growth pattern from an initially non-diffuse pattern (p = 0.42). Conclusions: The tumor growth and invasiveness patterns do not differ between BEV/IRI and TMZ-treated MGMT-non-methylated glioblastoma patients in the GLARIUS trial. BEV/IRI was not associated with an increased rate of multifocal, distant, or highly invasive tumors at the time of recurrence.

Details

OriginalspracheEnglisch
Seiten (von - bis)1581-1589
Seitenumfang9
FachzeitschriftJournal of cancer research and clinical oncology
Jahrgang144
Ausgabenummer8
PublikationsstatusVeröffentlicht - 1 Aug. 2018
Peer-Review-StatusJa

Externe IDs

PubMed 29808316

Schlagworte

Ziele für nachhaltige Entwicklung

ASJC Scopus Sachgebiete

Schlagwörter

  • Bevacizumab, MRI tumor growth patterns, Newly diagnosed MGMT-non-methylated glioblastoma, Progression patterns